Technical Analysis for ABIO - ARCA biopharma, Inc.

Grade Last Price % Change Price Change
grade D 2.425 -2.02% -0.05
ABIO closed down 2.02 percent on Friday, July 21, 2017, on 2.15 times normal volume. It was able to find support at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical ABIO trend table...

Date Alert Name Type % Chg
Jul 21 50 DMA Support Bullish 0.00%
Jul 21 200 DMA Resistance Bearish 0.00%
Jul 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jul 20 200 DMA Resistance Bearish -2.02%
Jul 20 Narrow Range Bar Range Contraction -2.02%

Older signals for ABIO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Get Started for Free!
Basic chart:

Profile
ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. ARCA biopharma, Inc. is headquartered in Broomfield, Colorado.
Is ABIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jun 20 ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis – DSMB Recommendation Anticipated in August 2017
May 15 ARCA Biopharma Announces First Quarter 2017 Financial Results and Provides Business Update
Apr 26 ARCA biopharma Announces 200th Patient Randomized into the GENETIC-AF Seamless Design Phase 2B/3 Clinical Trial
Apr 18 ARCA biopharma to Present at the Planet MicroCap Showcase 2017 Investor Conference
Mar 21 ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update
Mar 6 ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial
Feb 21 ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Feb 21 Anders Hove, MD Joins ARCA biopharma Board of Directors
Jan 18 ARCA biopharma Announces 150th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial
Jan 6 ARCA BIOPHARMA TO PRESENT AT BIOTECH SHOWCASE 2017
See more ABIO news...
Indicators
Indicator Value
52 Week High 3.21
52 Week Low 2.15
Average Volume 108,992
200-Day Moving Average 2.4827
50-Day Moving Average 2.4039
20-Day Moving Average 2.4613
10-Day Moving Average 2.4975
Average True Range 0.1175
ADX 18.97
+DI 18.07
-DI: 16.87
Chandelier Exit (Long, 3 ATRs) 2.3575
Chandelier Exit (Short, 3 ATRs) 2.7025
Upper Bollinger Band 2.637
Lower Bollinger Band 2.2856
Percent B (%b) 0.4
Bandwidth 0.14277
MACD Line 0.0171
MACD Signal Line 0.0254
MACD Histogram -0.0083